Ask AI
EU Focused MCL IDST
Interactive Decision Support Tool: EU-Focused MCL Expert Treatment Guidance

Released: May 27, 2026

About This Tool & Disclaimer

Interactive Decision Support Tool: EU-Focused MCL Expert Treatment Guidance

Decera Clinical Education is grateful to Maria Gomes da Silva, MD, PhD; Georg Hess, MD; Mats Jerkeman, MD, PhD; Ana Marin-Niebla, MD, PhD; and Carlo Visco, MD, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in May 2026 and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals on making optimal management choices for treating individuals with symptomatic stage III or IV mantle cell lymphoma (MCL).

A series of questions developed by the European Union (EU) experts allow the user to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include Mantle Cell Lymphoma International Prognostic Index (MIPI) score, age, TP53 mutation/TP53 overexpression status, prior therapies, and specific comorbidities. It should be noted that these factors are not exclusive when making choices; other patient and disease characteristics that are not included in this tool should also be considered, if appropriate, when making overall treatment choices.

This tool assumes a patient with symptomatic MCL but no additional features or comorbidities that would affect treatment choice other than those described when entering the patient details. Once the patient characteristics are entered into the tool, users will be asked to enter what their preferred treatment option will be. Afterward, an Expert Insight table showing the treatment choices of all 5 EU experts based on those same patient characteristics is displayed. Of note, all 5 EU experts provided the most preferred treatment recommendation based on the current approvals and/or actively recruiting phase III trial in the EU country in which each of them is currently practicing.

After viewing the answers from the Expert Insight panel, the tool will prompt the user to provide feedback about how the experts’ recommendations influenced their decision-making. Users are able to print out a complete report of their patient along with the Expert Insight recommendations.

For additional information on best practices in the management of patients with MCL, please read an expert-authored commentary and text module with embedded slides on treatment strategies to optimize MCL care as a helpful guide to learn more about important considerations before initiating treatment and optimal treatment sequencing for your patients with MCL.

This program is supported by an educational grant from AstraZeneca.

© 2026 Decera Clinical Education. All rights reserved.

This program is supported by an educational grant from AstraZeneca.

© 2026 Decera Clinical Education. All rights reserved.


The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Maria Gomes da Silva, MD, PhD: researcher: AstraZeneca; consultant/advisor/speaker: Janssen, Lilly, Roche; other financial or material support: AbbVie, BeOne, Gilead, Janssen, Lilly.

consultant: AbbVie, AstraZeneca, BeiGene/BeOne, Bristol Myers Squibb, Gilead/Kite, Incyte, Janssen, Miltenyi, Merck Sharp & Dohme, Pierre Fabre, Regeneron, Roche, Sobi; researcher (paid to institution): AbbVie, Gilead/Kite, Janssen, Lilly, Roche; other financial or material support: AbbVie, ADC, AstraZeneca, BeiGene, Bristol Myers Squibb, Gilead/Kite, Incyte, Janssen, Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sobi.

Mats Jerkeman, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Galapagos, Johnson & Johnson, Kite, Lilly, Sobi.

Ana Marin-Niebla, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene/BeOne, Johnson & Johnson, Takeda.

Carlo Visco, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Gilead, Johnson & Johnson, Incyte, Kyowa Kirin, Lilly, Novartis, Pfizer, Roche, Sobi, Takeda.

© 2026 Decera Clinical Education. All rights reserved.

Access to and use of this tool titled, “Interactive Decision Support Tool: EU-Focused MCL Expert Treatment Guidance” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for monitoring or treating individuals with mantle cell lymphoma. The information provided is based on guideline recommendations and expert guidance of Maria Gomes da Silva, MD, PhD; Georg Hess, MD; Mats Jerkeman, MD, PhD; Ana Marin-Niebla, MD, PhD; and Carlo Visco, MD.

The material published by Decera Clinical Education reflects the views of the reviewers or authors of the Decera Clinical Education material, not those of Decera Clinical Education, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the EMA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Decision Support Tool: EU-Focused MCL Expert Treatment Guidance” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2026 Decera Clinical Education. All rights reserved.

Program Content